NCT06611423View on ClinicalTrials.gov

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

August 21, 2025

Study Completion Date

August 21, 2025

Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)Renal Impairment
Interventions
BIOLOGICAL

AZD3427

AZD3427 SC injection to be prepared using AZD3427 diluent

OTHER

AZD3427 Placebo

AZD3427 Placebo

DRUG

Dopamine

Dopamine Hydrochloride 50mg/5mL

OTHER

Radiolabelled ligand

Injection of radioligand for PET examinations

OTHER

Saline

Saline solution

Trial Locations (1)

171 64

Research Site, Solna

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

Karolinska Institutet

OTHER

lead

AstraZeneca

INDUSTRY